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Abstract
Background: Interferon gamma (IFN-γ) is a clinically relevant immunomodulatory cytokine that has demonstrated
significant potential in the treatment and management of respiratory diseases such as tuberculosis and pulmonary
fibrosis. As with all large biomolecules, clinical translation is dependent on effective delivery to the disease site and
delivery of IFN-γ as an aerosol offers a logical means of drug targeting. Effective localization is often hampered by
instability and a lack of safe and efficient delivery systems. The present study sought to determine how effectively
IFN-γ can be nebulized using two types of vibrating mesh nebulizer, each with differing mesh architectures, and to
investigate the comparative efficiency of delivery of therapeutically active IFN-γ to the lungs.
Methods: Nebulization of IFN-γ was carried out using two different Aerogen vibrating mesh technologies with
differing mesh architectures. These technologies represent both a standard commercially available mesh type
(Aerogen Solo®) and a new iteration mesh (Photo-defined aperture plate (PDAP®). Extensive aerosol studies
(aerosol output and droplet analysis, non-invasive and invasive aerosol therapy) were conducted in line with
regulatory requirements and characterization of the stability and bioactivity of the IFN-γ post-nebulization was
confirmed using SDS-PAGE and stimulation of Human C-X-C motif chemokine 10 (CXCL 10) also known as
IFN-γ-induced protein 10KDa (IP 10) expression from THP-1 derived macrophages (THP-1 cells).
Results: Aerosol characterization studies indicated that a significant and reproducible dose of aerosolized IFN-
γ can be delivered using both vibrating mesh technologies. Nebulization using both devices resulted in an
emitted dose of at least 93% (100% dose minus residual volume) for IFN-γ. Characterization of aerosolized
IFN-γ indicated that the PDAP was capable of generating droplets with a significantly lower mass median
aerodynamic diameter (MMAD) with values of 2.79 ± 0.29 μm and 4.39 ± 0.25 μm for the PDAP and Solo respectively. The
volume median diameters (VMD) of aerosolized IFN-γ corroborated this with VMDs of 2.33 ± 0.02 μm for the PDAP and 4.
30 ± 0.02 μm for the Solo. SDS-PAGE gels indicated that IFN-γ remains stable after nebulization by both devices and this
was confirmed by bioactivity studies using a THP-1 cell model in which an alveolar macrophage response to IFN-γ was
determined. IFN-γ nebulized by the PDAP and Solo devices had no significant effect on the key inflammatory biomarker
cytokine IP-10 release from this model in comparison to non-nebulized controls. Here we demonstrate that it is possible
to combine IFN-γ with vibrating mesh nebulizer devices and facilitate effective aerosolisation with minimal impact on IFN-
γ structure or bioactivity.
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Conclusions: It is possible to nebulize IFN-γ effectively with vibrating mesh nebulizer devices without compromising its
stability. The PDAP allows for generation of IFN-γ aerosols with improved aerodynamic properties thereby increasing its
potential efficiency for lower respiratory tract deposition over current technology, whilst maintaining the integrity and
bioactivity of IFN-γ. This delivery modality therefore offers a rational means of facilitating the clinical translation of inhaled
IFN-γ.
Keywords: Idiopathic pulmonary fibrosis, Tuberculosis, Interferon gamma, Inhaled therapy, Vibrating mesh, Nebulizer,
Aerosol
Background
Cytokines, including the interferons (IFNs), play an es-
sential role in immune and inflammatory responses [1].
The IFNs are subdivided into two classes (Type I and
Type II) based on their sequence and specificity for par-
ticular receptors. Type II includes a single and distinct
molecule, IFN-γ which is produced in activated T-cells
and natural killer cells in response to interleukin (IL)-12
and IL-18 being produced by antigen presenting cells
[2]. These important molecules are involved in the
underlying pathophysiology of a number of infectious
and inflammatory associated disease states including
idiopathic pulmonary fibrosis (IPF), tuberculosis (TB),
osteoporosis, chronic granulomatous disease (CGD) and
systemic lupus erythematous (SLE) among others [3].
IFN-γ is used clinically in the management of CGD
(resulting from leukocyte dysfunction) and severe malig-
nant osteoporosis (a congenital disorder associated with
increased bone density due to impaired resorption of os-
teoclasts). Both conditions result in patients regularly
suffering from life threatening infections. Prophylactic
treatment with IFN-γ reduces the frequency and relative
risk of severe infections and may delay disease progres-
sion [4]. Currently, two recombinant IFN-γ products are
available; Actimmune® (Horizon Pharma USA, Inc) and
Immukin® (Boehringer Ingelheim, Germany). These
identical liquid preparations are only licensed at present
for the aforementioned conditions and only for paren-
teral administration [1]. Current research is focusing on
alternative applications for IFN-γ, and is largely under-
pinned by an assumption that therapeutic effects are due
to its immunomodulatory properties [5, 6].
Within respiratory medicine there is a growing interest
in a potential role for IFN-γ in the treatment of IPF, TB
and other inflammatory respiratory conditions [7]. A
multinational study of 330 IPF patients showing the sub-
cutaneous administration of IFN-γ versus placebo, con-
cluded that IFN-γ did not affect progression-free survival,
pulmonary function, or the quality of life [8]. However,
this study also concluded that due to the size of the pa-
tient population and trial duration, a clinically significant
survival benefit could not be ruled out. Work such as this
has led researchers to explore direct, targeted delivery of
the biomolecule via inhalation, as an alternative route of
administration to injection. There are various aerosol de-
livery modalities. Aerosols may be delivered via an endo-
tracheal tube. In this modality, the patient will be under
direct clinical supervision and therefore in a hospital or
clinical setting. Inhalation of aerosol formulations may
also via a non-invasive route of administration, e.g. face-
mask, with the potential for targeted delivery within the
lung, and consequent improved clinical response with
minimal adverse effects [9]. A study on healthy volunteers
comparing parenterally delivered to aerosolized IFN-γ,
showed that subcutaneous administration resulted in de-
tectable levels of IFN-γ in serum, but not in epithelial lin-
ing fluid (ELF) [10, 11]. There was also evidence of IP-10
expression (a gene induced specifically by IFN-γ) in blood
monocytes but not alveolar macrophages in the lungs, in
addition to multiple systemic adverse effects. Inhaled
IFN-γ on the other hand was not detectable in serum but
was detectable in respiratory ELF, in a dose dependent
fashion. Alveolar macrophages, but not blood monocytes,
expressed IP-10 mRNA transcripts, and delivery via inhal-
ation precipitated negligible local or systemic adverse
effects.
Aerosolized IFN-γ has been used in numerous clinical
trials in combination with other standard treatments.
For example, Moss and colleagues [12] administered
Actimmune via a jet nebulizer to CF patients and deter-
mined 12 week outcomes. Whilst it was well-tolerated,
there was no significant benefit in terms of patient out-
comes with inflammatory sputum markers, bacterial
load and lung function all remaining the same. Others
have also investigated the aerosolisation of IFN-γ for ap-
plication in both TB and IPF [13]. Increasing resistance
to TB therapies is a global medical challenge resulting in
complicated, lengthier and more toxic treatment regi-
mens and an ever-limited range of treatment options
[14]. A trial of inhaled IFN-γ in multi-drug resistant TB
showed that, similar to Moss and colleagues, it was well
tolerated [15]. There was also evidence in this study of
improvement in symptoms with topography chest scans
showing a reduction in cavity lesion size, reduced
bacterial loads for acid-fast-bacillus in sputum and
Mycobacterium tuberculosis.
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Nebulizers facilitate drug delivery to the lungs in the
form of an aerosolized drug solution or suspension with
properties including droplet size distribution of the
emitted aerosols and output rate considered key to aero-
sol generator performance and ultimate drug deposition
profiles within the lungs [16, 17]. Nebulizers can be very
beneficial in treating patients with significant respiratory
disease and compromised lung function with a reduced
dependence on patient inspiratory flow for delivery com-
pared to other inhaler devices [18]. This results in these
target patients receiving enhanced delivery and im-
proved disease outcomes [17]. They are also beneficial
for patients with tracheostomies, those requiring mech-
anical ventilation and paediatric patients [19, 20]. How-
ever, nebuliser’s are not without their limitations; in
addition to their often cumbersome and noisy nature,
nebulizer technologies including jet and ultrasonic nebu-
lizers are unsuitable for the aerosolisation of some bio-
molecules with issues associated with both delivery
efficiency and biomolecule stability [21]. Vibrating mesh
nebulizers (VMNs) which are the focus of this study are
aerosol generators that convert a liquid drug solution or
suspension into an aerosol. VMNs however, offer a po-
tential means of nebulizing biomolecules effectively
without affecting stability [22]. The selected devices in
this study are particularly suitable for delivery of biomol-
ecules such as IFN-γ as less stress is put on the thera-
peutic cargo than that imposed by a jet or ultrasonic
nebulizer. Ultrasonic and jet nebulizers may damage
protein and other complex agents through heat or shear
stress [23].
Studies to date have focused on the safety and efficacy
profile of nebulized IFN-γ but not on the aerosol prop-
erties or pharmaceutical characteristics including stabil-
ity of the IFN-γ post-nebulization. Nebulizers used
include the Respirgard II jet nebulizer [12], the PARI
BOY N® jet nebulizer [24], and the ultrasonic I-neb
Adaptive Aerosol Delivery System [25]. Here, we
aerosolized IFN-γ using a commercially available
vibrating-mesh technology (Aerogen Solo) and a novel
mesh technology (PDAP, also developed by Aerogen).
The novel PDAP device was designed to facilitate both
low droplet size and faster flow rates, allowing poten-
tially for more precise delivery to specific target areas
within the airways. This unique combination of higher
output rate and lower droplet size could potentially
reduce treatment times whilst enabling deposition of a
greater portion of the therapeutic aerosol in the lower
airways. Herein we challenge the utility of this novel
technology in combination with IFN-γ, a classically
difficult-to-deliver biomolecule cargo of clinical interest,
and compare its performance to the current mesh tech-
nology, embodied in the Aerogen Solo, and already re-
ported as used in the delivery of IFN-γ.
In order to determine the utility of both iterations of
vibrating mesh technology for IFN-γ aerosolisation,
extensive aerosol performance assessments were com-
pleted which included; delivered dose, post-nebulization
stability and activity, MMAD, VMD and output rate
(ml/min).
Materials and methods
Interferon Gamma
Immukin® (IFN-γ), Boehringer Ingelheim Immukin was
purchased from Uniphar Group, Dublin, Ireland and used
in all experimental work. Human IFN-γ enzyme-linked
immunosorbent assay (ELISA) MAX™ Deluxe kit and
Human CXCL 10 (IP 10) ELISA MAX™ were obtained
from BioLegend, San Diego, CA 92121. All other materials
unless specified were purchased from Sigma Aldrich,
Ireland.
Vibrating mesh Nebulisers (VMN)
Two vibrating mesh-type nebulizers (Aerogen Solo and
Aerogen PDAP, Aerogen, Galway, Ireland) were assessed
in this study. The Aerogen Solo is a single layer
photo-defined vibrating mesh which has a 5mm aperture
plate diameter, perforated with 1000 precision formed
holes, vibrating at 128,000 times per second. This mesh
produces droplets 1–5 μm in diameter and is made from
Nickel/Palladium mix. The overall thickness is ~ 60 μM.
The Aerogen PDAP is a photo defined 2-layer vibrating
mesh, also produced using a Nickel/ Palladium mix. It also
has a 5mm aperture plate diameter (defined by the phys-
ical properties as demonstrated in Fig. 1 below) with
15,800 holes, also vibrating at 128,000 times per second.
Emitted dose characterization
A known concentration (500, 250, 125 pg/mL) in 1 ml
IFN-γ was nebulized using either the Aerogen Solo or
PDAP mesh technology. The respective aerosols pro-
duced were captured directly in a sealed 50 mL tube.
Following complete nebulization of the dose, the device
was powered off, removed and the tube centrifuged
(Hettich Rotina 35R Bench centrifuge, 5 mins, 10,000
rpm) in order to pool the sample prior to refrigeration
at 4-8 °C. The concentration of delivered dose was deter-
mined using a Human IFN-γ ELISA MAX™ Deluxe kit
(BioLegend, San Diego, CA 92121) as per kit instruc-
tions. The medication cup of both the Solo and PDAP
were washed and residual volume calculated.
Aerosol output rate and droplet size characterization
VMD and aerosol output rate were determined using
laser diffraction (Malvern Spraytec, Malvern, UK) as pre-
viously described [26]. The MMAD of each aerosol was
also determined by cascade impaction at 15 litres per
minute (LPM) (Next Generation Impactor (NGI), Copley
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Scientific, UK) [27]. For each replicate, a fixed volume of
0.5 mL of 6.25 μg/ml IFN-γ was aerosolized. Gravimetric
measures were used to determine the distribution of
aerosol droplets across the impactor stages. Prior to and
post runs, nebulizers and NGI cups were weighed using
an electronic analytical balance (OHAUS Pioneer®,
Switzerland). The MMAD, and geometric standard devi-
ation (GSD) were calculated using validated software
(CITDAS version 3.10 Copley, UK). Triplicate runs were
performed for each device.
Simulated aerosol delivery during a non-invasive patient
intervention – spontaneous breathing
Non-invasive Nasal High Flow therapy is increasingly used
across a variety of patient populations and so it may be
beneficial to combine this intervention with inhaled drug
therapy including biomolecules [28]. Investigations by
Branconnier and colleagues [29] determining non-invasive
nasal high flow therapy-nebulizer compatibility employed
albuterol sulphate as an exemplar drug, as have studies by
Diaz and colleagues [25], and our own colleagues [30]. We
chose to use albuterol as a tracer aerosol (see study limita-
tions). Albuterol is a commonly nebulized bronchodilator,
regularly reported in the aerosol therapy literature as a
means of aerosol performance characterization. Albuterol
sulphate is also specified for use as a tracer aerosol in the
international standard ISO 27427:2013. The Ingmar ASL
5000 breathing apparatus was used to simulate a healthy
adult (15 BPM, Vt 500ML, I/E 1:1) [31]. An adult high
flow nasal therapy system (Optiflow™, Fisher and Paykel)
was attached to a humidifier (MR850™, Fisher and Paykel)
set at 37 °C. The nebulizers were placed at the humidifier,
in line with previous findings for maximal aerosol delivery
during high flow therapy [30]. 2 ml of 2mg/ml Albuterol
sulphate solution was nebulized by both the Aerogen Solo
and PDAP mesh devices. Tracheal Dose [Dose delivered
beyond the trachea] at each gas flow rate under test (10,
30, 45 LPM) was recorded on an absolute filter (Respir-
gard 303, Baxter) distal to the adult airway model (n = 3)
as shown in Fig. 2. The mass of drug eluted from the fil-
ters was determined using UV spectroscopy (276 nm) and
interpolation on a standard curve of albuterol sulphate
concentrations.
Simulated aerosol delivery during an invasive patient
intervention – mechanical ventilation
In line with the non-invasive delivery modality investiga-
tions, albuterol sulphate served as a surrogate drug for
Fig. 1 Mesh architecture: a General perspective view of reservoir wells on a thick support layer overlaid on a thin outlet layer as captured by scanning
electron microscope (SEM) (Magnification 817x). b Reservoir image of the PDAP (photo defined aperture plate) device as captured by SEM.
c Outlet holes of the PDAP device aperture plate as captured by SEM. d Solo and PDAP mesh housing
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IFN-γ during simulated invasive mechanical ventilation
via an endotracheal tube. The Maquet Servo-i ventilator
was used to generate an adult breathing pattern (Volume
Control Ventilation, 15 BPM, 500ml Vt, I:E 1:2, PEEP
5cmH20) with a 22 mm endotracheal tube. Albuterol
sulphate (2 ml of 2 mg/ml solution) was nebulized by
both the Aerogen Solo and PDAP devices. Both the
Aerogen Solo and PDAP nebulizers were placed between
the wye and endotracheal tube (Flexicare, 038–961-080,
ID 8.0 mm, UK). The inhaled dose was recorded on an
absolute filter (Respirgard 303, Baxter, Ireland) distal to
the ETT (n = 3). The mass of drug eluted from the filters
was again determined using UV spectroscopy (276 nm)
and interpolation on a standard curve of albuterol
sulphate concentrations.
Bioactivity assay
Electrophoresis was carried out using XCell SureLock®
NuPAGE Bis-Tris Mini Gels 4–12%. Protein samples
(25 μg/ml) were prepared as per manufacturer
guidelines.
CXCL 10, also known as IP 10 is a key biomarker in many
disease states and plays a significant role following IFN-γ in-
duced release, in many inflammatory conditions including
those affecting the pulmonary system. There is a positive
feedback loop between IFN-γ release by ThP-1 cells and
IP10 release thus interruption of the loop can alter the in-
flammatory response produced [32]. ThP-1 cells stimulated
with IFN-γ release IP10 and as such can be used to
determine the bioactivity of nebulized IFN-γ. ThP-1 cells
were grown in RPMI 1640 media containing 10% foetal bo-
vine serum supplemented with 100 μg/ml penicillin, 100 μg/
ml streptomycin and 2mmol/l L-glutamine and maintained
in a 5% CO2 incubator at 37 °C.
For the bioactivity assay of post-nebulized IFN-γ, ThP-1
cells were seeded at a density of 1X105 cells/ml in a 24
well plate and differentiated for three days with phorbol
myristate acetate (PMA) prepared as a stock solution (10
mM) in dimethyl sulfoxide and diluted to a final concen-
tration 100 nM in media. Following differentiation media
was removed and replaced with media containing a
known concentration (20, 10, 5 ng/ml) of non-nebulized
(control) and nebulized IFN-γ. After 24 h the supernatants
were collected and the amount of released CXCL 10 (IP
10) was measured by ELISA (Human CXCL 10 (IP 10)
ELISA MAX™ Deluxe kit) using the ELISA kit protocol.
Statistical analysis
Data were expressed as mean ± standard error. All statis-
tical analyses were conducted using.
GraphPad Prism 5 software (GraphPad, San Diego,
CA, USA). Data were analyzed by a two-way Anova. A P
value of less than 0.05 was deemed significant.
Results
Emitted dose
IFN-γ at three differing concentrations (500, 250, 125
pg/ml) was quantified postnebulization using the Solo
Fig. 2 Tracheal Dose test setup with high flow nasal cannula, showing the adult head model attached to the breathing simulator
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and PDAP devices and compared to non-nebulized con-
trols. The amount of IFN-γ emitted by each device was
determined by ELISA, as previously described.
Non-nebulized controls were assayed for each concen-
tration and as shown in Fig. 3 proved to be 101.80%
(509.28 pg/ml ± 30.78), 97.22 (243.04 pg/ml ± 23.30) and
103.47% (129.34 pg/ml ± 15.062) recovered for each of
the doses 500, 250, and 125 pg/ml respectively (n = 6).
There was no significant difference in the amount of
IFN-γ retrieved post-nebulization using the either the
Solo (99.59%: 497.96 pg/ml ± 2.901, 101.62%: 254.042 pg/
ml ± 4.74 and 99.07%: 123.84 pg/ml ± 3.66) or PDAP de-
vices (106.59%: 532.97 pg/ml ± 47.858, 107.60%: 268.99
pg/ml ± 31.584 and 93.81%: 117.26 pg/ml ± 19.37). Thus
it can be concluded that nebulization using either device
results in at least 93% dose delivery for IFN-γ and in
terms of dose delivery the PDAP matches closely that
achieved with the commercially available Solo device.
With the balance remaining as residual within the medi-
cation cup.
Aerosol output and droplet size characterization
Both mesh iterations were investigated for their ability
to aerosolize a 0.5 ml dose of 6.25 μg/ml (chosen origin-
ally due to detection limits of ELISA plates) of IFN-γ
with droplet size and aerosol output rates. Copley soft-
ware facilitated calculation of MMAD and GSD of nebu-
lized droplets (results shown in Table 1). The output
rate proved similar for the test VMNs (PDAP: 0.44 ml/
min in comparison with 0.42ml/min for Aerogen Solo)
however droplet size differed significantly between the
devices with VMD and MMAD values for Aerogen Solo
almost twice those produced but the PDAP. In both
cases however, the nebulizers produced IFN-γ droplets
suitable for pulmonary delivery with droplets falling
within the optimal MMAD/ respirable range of 0.5–5 μm
[16]. The PDAP device however, may be more suitable for
drug delivery to the lower airways as both the VMD and
MMAD indicate that it produces significantly smaller
droplets 2.33 μm, 2.79 μm with GSD 1.47 μm respectively
in comparison to 4.39 μm, 4.30 μm and GSD 1.90 μm for
Aerogen Solo. In Table 1, P-values of < 0.0001 for VMD
and 0.0005 for MMAD indicate that a statistical difference
for both MMAD and VMD exists between the two
devices.
Aerosol delivery during simulated non-invasive
ventilation
The Ingmar ASL 5000 breathing apparatus was used to
simulate a healthy adult. Albuterol sulphate was deliv-
ered via an adult nasal high flow interface at varying
clinically relevant gas flow rates. Within respiratory
medicine there is a growing interest in a potential role
for IFN-γ in the treatment of IPF, TB and other inflam-
matory respiratory conditions. This has led researchers
to explore direct, targeted delivery of the biomolecule
via inhalation, as an alternative route of administration
to injection. This patient acceptable, easy to use and
non-invasive delivery system offers targeted delivery for
respiratory diseases thus improved clinical response with
minimal adverse effects [33]. The results of testing are
presented in Table 2. Results are expressed as a percent-
age of the nominal dose placed in the nebulizer medica-
tion cup.
The data presented in Table 2 indicates that across all
three gas flow rates investigated, the difference between
Fig. 3 IFN-γ recovery (pg) of 1 ml dose volumes of known doses of IFN-γ (500–125 pg/ml) using both VMNs (vibrating mesh nebulizer’s) - Solo
and PDAP devices. Results were compared to non-nebulized controls (n = 6)
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both test devices is significant, with P-values of < 0.0001,
0.0002 and 0.0008 at 10, 30 and 45 LPM respectively.
The PDAP device delivered a higher tracheal dose for all
gas flow rates used in this study. This suggests that a pa-
tient would receive more drug than when using the Solo
device [7]. It can also be seen that an increase in gas
flow rate leads to a reduction in efficiency. This may be
due to particle collisions in the circuit and also within
the head model itself. MacLoughlin and colleagues [34]
previously reported that higher flow rates are associated
with reduced efficiency of drug delivery through an adult
NHF system.
Aerosol delivery during simulated invasive mechanical
ventilation
The Maquet Servo-i ventilator was used to generate a
healthy adult breathing pattern as described in Table 3.
Inhaled dose at the end of an 8.0 mm adult ETT was de-
termined. This test is to determine (as a percentage) in-
haled dose delivered to the patient in a clinical or
hospital setting. The results of testing are presented in
Table 3. Results are expressed as a percentage of the
nominal dose placed in the nebulizer medication cup.
Table 3, shows a statistically significant difference be-
tween the percentage inhaled dose mean for the Aero-
gen Solo and PDAP at 18.31 and 24.58%, respectively.
As with non-invasive therapy the PDAP device is more
efficient in this study. This means the patient is inhaling
a higher dose when compared to the Solo.
Protein stability post-nebulization
IFN-γ was assessed for molecular weight and signs of
degradation using SDS-PAGE post-nebulization. Three
samples nebulized through the Aerogen Solo and three
nebulized though the PDAP device were loaded onto a
SDS-PAGE gel as shown in Fig. 4 (25 μl of boiled protein
25 μg/ml). Nebulized IFN-γ using Aerogen Solo® (lanes
4, 5 and 6) and PDAP device (lanes 7, 8 and 9) exhibited
no changes in molecular weight or detectable degrad-
ation compared to non-nebulized controls (lanes 2 and
3) as evidenced by no change in bands on the gel.
Bioactivity of nebulized IFN-γ
The bioactivity of nebulized IFN-γ was determined using
THP-1 cells. Cells were activated using PMA (100 nM)
and treated with bioactive IFN-γ. The chemokine
CXCL10 subsequently released into cell culture super-
natant, the quantity of which was determined by ELISA
and validated using non-nebulized IFN-γ. IFN-γ at a
range of concentrations, 10 and 5 ng/ml, was nebulized
using both devices (Aerogen Solo® and PDAP devices)
and exposed to activated THP-1 cells in culture for 24 h.
As seen in Fig. 5 (n = 5) there was no statistical differ-
ence in the amount of CXCL 10 (IP 10) released by
THP-1 cells when stimulated with doses of nebulized
IFN-γ (10 and 5 ng/ml) from the Aerogen Solo at
(4205.75 pg/ml ± 776.859 and 2180.049 pg/ml ± 313.049
respectively) or PDAP device (4295.399 pg/ml ± 779.966
and 2519.717 pg/ml ± 396.657 respectively) in compari-
son to non-nebulized controls at 5 ng/ml4063.351 pg/ml
± 715.944 and 10 ng/ml 2269.230 pg/ml ± 313.049. RPMI
media alone and IFN-γ drug diluent served as controls
and there was no detectable CXCL 10 (IP 10) in IFN-γ
free supernatants. Bioactivity findings suggest that there
is no detrimental effect on the IFN-γ structure and func-
tion during nebulization using both vibrating mesh tech-
nologies tested and that nebulized IFN-γ effectively
stimulated IP 10 release from activated THP-1 cells.
Table 1 The volume median diameter (VMD), mass mean aerodynamic diameter (MMAD) and geometric standard deviation (GSD)
of IFN-γ aerosol droplets produced by the test devices (PDAP and Aerogen Solo). P-values < 0.05 were considered significant
Vibrating mesh type VMD (μm) MMAD (μm) GSD (μm) based on MMAD values
PDAP 2.33 ± 0.02 2.79 ± 0.29 1.47 ± 0.07
Solo 4.39 ± 0.02 4.30 ± 0.25 1.90 ± 0.04
P-value < 0.0001 0.0005 N/A
Table 2 Mean tracheal dose delivered of albuterol sulphate (2mg/
ml) a surrogate drug for IFN-γ using the LUCY adult airway model
and test devices (PDAP and Aerogen Solo)(n= 3). P-values < 0.05
were considered significant
Gas
Flow Rate
(LPM)
PDAP Solo P-value
(%) Tracheal
Dose Mean (± STDEV)
10 27.32 ± 0.47 22.45 ± 0.19 < 0.0001
30 21.35 ± 0.64 15.67 ± 0.45 0.0002
45 9.54 ± 0.85 5.10 ± 0.07 0.0008
Table 3 Mean Inhaled dose delivered of albuterol sulphate (2mg/
ml) a surrogate drug for IFN-γ using adult breathing parameters
during mechanical ventilation and test devices (PDAP and Aerogen
Solo) (n= 3). P-values < 0.05 were considered significant
PDAP Solo P-value
Inhaled Dose Mean
(%)(± STDEV)
24.58 ± 0.21 18.31 ± 0.45 < 0.0001
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Study limitations
Although the findings are promising we recognize that
there are limitations to our study. Namely, albuterol
sulphate was used as a surrogate drug for IFN-γ for both
simulated non-invasive and invasive aerosol therapy. In
our hands, it was not possible to produce an accurate re-
liable quantification method for IFN-γ, despite using
commercially available kits and following the published
literature. It is possible that the IFN-γ was binding to
the filter plastics. We also recognize that this is a
pre-clinical study and despite our findings indicating
effective nebulization of IFN-γ using VMNs it remains
to be seen whether these effects are transferable to a
clinical environment.
Discussion
New inhalation devices are enabling the delivery of large
biomolecules directly to the lungs. This provides oppor-
tunities for the translation of advanced therapies for re-
spiratory disease via the inhaled route. Typically, biologics
in the clinic are parenterally administered. Extensive clin-
ical work has been conducted by others regarding the
safety and therapeutic efficacy of inhaled IFN-γ [35], how-
ever, very limited data is available to-date on the aerosol
and pharmaceutical characteristics of nebulized IFN-γ.
Such information could inform appropriate or improved
device selection and consequently may have a significant
effect on clinical outcomes. In this work, we have investi-
gated the performance of two VMNs; a marketed model
Aerogen Solo, and a novel Aerogen PDAP device for de-
livery of IFN-γ.
Aerosolized droplets intended for inhalation must be
appropriately sized (1–5 μm) to achieve optimal depos-
ition in the lungs. Smaller aerosols (closer to 1 μm in size)
are capable of much deeper delivery, whilst those greater
than 5 μm are deposited in the pharynx, and those less
than 0.5 μm are likely exhaled prior to deposition [16]. In
addition, the recovered dose (100% dose - Residual vol-
ume) is an important factor from a therapeutic perspective
with a drugs’ efficacy being linked to the properties of
both the nebulizer and amount of available aerosolized
drug. Our findings indicate that both nebulizers are effi-
cient at delivering at least 93% of a known dose of IFN-γ
Fig. 4 SDS-PAGE analysis indicated that IFN-γ remained intact post-nebulization from both devices Aerogen Solo (lanes 4–6) and PDAP
(lanes 7–9) in comparison to non-nebulized controls (lanes 2–3). The molecular weight marker is in lane 1
Fig. 5 CXCL-10 release from THP-1 cells (n = 5) following treatment
with nebulized IFN-γ (using Solo and PDAP devices) and non-nebulized
(control) IFN-γ at 10 and 5 ng/ml. Two additional controls were
employed RPMI and IFN-γ diluent and were non-detectable (ND)
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(500, 250, 125 pg/mL), which is significantly higher than
that reported for other nebulizer technologies [36] .
We conducted aerosol output and droplet size analysis
to verify that VMNs are capable of delivering IFN-γ at
an acceptable rate, and that the aerosols produced are
appropriately sized. This builds on work of others relat-
ing to aerosolisation of IFN-γ and further supports its
potential use as inhaled therapy for inflammatory
respiratory conditions such as TB and IPF. Aerosol stud-
ies indicated that there was no significant difference be-
tween the devices with respect to output rate (PDAP:
0.44 ml/min V Aerogen Solo: 0.42 ml/min). There were
however statistically significant differences in aero-
dynamic particle size distributions for aerosols produced
from the two VMNs with the PDAP producing much
smaller VMD, MMAD and GSD values (2.33, 2.79 and
1.47 μm respectively). Aerosol droplets of IFN-γ pro-
duced by the PDAP had a smaller MMAD than seen in
a previous study that nebulized IFN-γ (Immukin) using
a PARI jet nebulizer (MMAD 3.7 μm) [24]. Diaz and col-
leagues [25] have shown that radio-labelling of IFN-γ
permits imaging of lung deposition in patients.
Radio-labelled IFN-γ nebulized using a VMN (I-neb
Adaptive Aerosol Delivery System) produced droplets of
similar size to those produced by the PDAP device in-
vestigated in our study (2.8 μm). Droplets of this size
were suitably sized to reach the middle lobe area in the
lungs. The ability of PDAP to generate droplets of a
smaller aerodynamic size could offer advantages over
currently marketed devices in terms of targeting IFN-γ
to the distal airways for treatment of TB and/or IPF.
The surrogate drug albuterol (specified for use as a
tracer aerosol in the international standard ISO
27427:2013) was delivered with the Aerogen PDAP and
compared to the commercially available Aerogen Solo.
For both simulated non-invasive and invasive patient in-
terventions that facilitate concurrent aerosol therapy, the
PDAP demonstrates improvements in efficiency for both
tracheal and inhaled dose when compared to the Aero-
gen Solo.
SDS-PAGE indicates that IFN-γ remains structurally
intact following nebulization using both vibrating mesh
technologies. This also confirms that the droplets pro-
duced and measured in NGI studies are aerosolized
IFN-γ and not breakdown products. VMNs such as
those tested in this study therefore appear to be suitable
delivery methods for IFN-γ. Uniquely, the PDAP facili-
tied a fast output rate (0.44 ml/min) in conjunction with
a small droplet size (2.79 μm MMAD), optimal for lung
targeting. Further confirmation of drug stability
post-nebulization was determined through bioactivity as-
says. THP-1 cells differentiated into macrophages were
used to conduct IFN-γ bioactivity, studies. THP-1 cells
are considered as suitable models for determining
alveolar macrophage response (including cytokine
CXCL10 release) to IFN-γ. Increased CXCL10 levels are
associated with many inflammatory pulmonary condi-
tions including asthma thus CXCL10 expression, and re-
ceptors, are potential targets for novel therapies
including inhaled IFN-γ [37]. Raju and colleagues [38]
demonstrated that IFN-γ treated THP-1 cells displayed a
similar increase in CXCL10 expression to those exposed
to TB infections, and the combination of TB infection
and IFN-γ further increased IP10 release. We observed
CXCL10 release following exposure of THP-1 cells to
control (non-nebulized) IFN-γ. Nebulization using
VMNs did not affect the bioactivity of IFN-γ, as there
was no statistical difference between CXCL10 release
elicited by nebulized IFN-γ and non-nebulized IFN-γ
controls. This confirms the potential of both VMN de-
vices (Solo and the PDAP) to deliver therapeutically ac-
tive IFN-γ via nebulization in an in vitro setting.
Efficient delivery of IFN-γ locally to TB and/or IPF pa-
tients via nebulization could support a patient-friendly,
targeted approach to treatment and potentially improve
therapeutic outcomes as shown in clinical studies [24].
Conclusions
Whilst further clinical evaluation is required, using inter-
national standard methodologies for the assessment of
nebulizer performance in patients, we have demonstrated
the feasibility of an alternative nebulizer type to the com-
monly reported jet nebulizer type for the aerosol-mediated
delivery of IFN-γ pre-clinically. The new iteration of mesh
technology, the Aerogen PDAP, serves to improve delivery
efficiency of IFN-γ delivery over the current Solo device.
Our findings show that the integrity and bioactivity of
IFN-γ are maintained post-nebulization using the new
VMN. This device therefore offers a rational means of fa-
cilitating the clinical translation of inhaled IFN-γ for appli-
cation in diseases such as IPF and TB.
Abbreviations
(ELF: epithelial lining fluid; ASL: active servo lung; CGD: chronic
granulomatous disease; CXCL 10: C-X-C motif chemokine 10; ELISA: enzyme-
linked immunosorbent assay; GSD: gravimetric standard deviation;
IFNs: interferons; IFN-γ: Interferon gamma; IL: interleukin; IP 10: IFN-γ-induced
protein 10KDa; IPF: idiopathic pulmonary fibrosis; LPM: liters per minute;
MMAD: mass median aerodynamic diameter; NGI: next generation impactor;
PDAP: photo-defined aperture plate; PMA: phorbol myristate acetate;
SEM: scanning electron microscopy; SLE: systemic lupus erythematous;
TB: tuberculosis; THP-1 cells: THP-1 derived macrophages; VMD: volume
median diameter; VMNs: vibrating mesh nebulizers
Acknowledgements
Not applicable.
Funding
The authors would like to acknowledge funding from Science Foundation
Ireland (SFI) as part of the Centre for Research in Medical Devices (CÚRAM)
13/RC/2073.
Sweeney et al. Respiratory Research           (2019) 20:66 Page 9 of 11
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
Acquisition of data: LS, GH, AMC, JR. Analysis and Interpretation of data: LS,
AMC, GH, JMR, SAC and RML. Drafting of Manuscript: LS, AMC, GH, JMR.
Study concept, design and guidance, and review of manuscript: SAC, RML.
All authors read and approved final manuscript.
Ethics approval and consent to participate
Not Applicable.
Consent for publication
Not Applicable.
Competing interests
Ronan MacLoughlin and Louise Sweeney are employees of Aerogen, the
manufacturer of the vibrating mesh nebulizers described in this study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Aerogen, IDA Business Park, Dangan, Galway, Ireland. 2School of Pharmacy,
RCSI, Dublin, Ireland. 3Tissue Engineering Research Group (TERG), RCSI,
Dublin, Ireland. 4Trinity Centre for Bioengineering (TCBE), TCD, Dublin,
Ireland. 5School of Pharmacy and Pharmaceutical Sciences, Trinity College,
Dublin, Ireland. 6Centre for Research in Medical Devices (CÚRAM) NUIG &
RCSI, Dublin, Ireland.
Received: 9 November 2018 Accepted: 21 March 2019
References
1. Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A, et al.
Formulation and Stability of Cytokine Therapeutics. J Pharm Sci [Internet].
Elsevier; 2015 [cited 2019 Mar 5];104:307–26. Available from: https://www.
sciencedirect.com/science/article/pii/S0022354915302161
2. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-γ: an overview of
signals, mechanisms and functions. J Leukoc Biol. 2003;75:163–89.
3. Miller CHT, Maher SG, Young HA. Clinical use of interferon-γ. Ann N Y Acad
Sci Wiley/Blackwell (10.1111); 2009;1182:69–79.
4. Lyseng-Williamson KA. Interferon γ-1b in chronic granulomatous disease
and severe malignant osteopetrosis: a guide to its use in the USA. Drugs
Ther Perspect. 2015;31:213–20.
5. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer
Res. 2011:6118–24.
6. Greenlee-Wacker MC, Nauseef WM. IFN-γ targets macrophage-mediated
immune responses toward Staphylococcus aureus. J Leukoc Biol Wiley-
Blackwell; 2017;101:751–758.
7. Smaldone GC. Repurposing of gamma interferon via inhalation delivery.
Adv Drug Deliv Rev. 2018;133:87–92.
8. Raghu G, Brown KK, Williamson Z, Bradford WZ, Starko K, Noble PW,
Schwartz DA, King TE. A placebo-controlled trial of interferon gamma-1b in
patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–33.
9. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv
Drug Deliv Rev. 1996:3–36.
10. Jaffe HA, Buhl R, Mastrangeli A, Holroyd KJ, Saltini C, Czerski D, et al.
Organ specific cytokine therapy. Local activation of mononuclear
phagocytes by delivery of an aerosol of recombinant interferon-gamma
to the human lung. J Clin Invest American Society for Clinical
Investigation. 1991;88:297–302.
11. Fusiak T, Smaldone GC, Condos R. Pulmonary fibrosis treated with inhaled
interferon-gamma (IFN-γ). J Aerosol Med Pulm Drug Deliv. 2015;28:406–10.
12. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, et al.
Randomized, double-blind, placebo-controlled, dose-escalating study of
aerosolized interferon gamma-1b in patients with mild to moderate cystic
fibrosis lung disease. Pediatr Pulmonol. 2005;39:209–18.
13. Condos R, Hull FP, Schluger NW, Rom WN, Smaldone GC. Regional
deposition of aerosolized interferon-gamma in pulmonary tuberculosis.
Chest. Elsevier; 2004;125:2146–2155.
14. Millard J, Ugarte-, Gil C, Moore. Multidrug resistant tuberculosis BMJ 2015;
350–882.
15. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant
pulmonary tuberculosis with interferon-γ via aerosol. Lancet. 1997;349:
1513–5.
16. Mortensen NP, Durham P, Hickey AJ. The role of particle physico-chemical
properties in pulmonary drug delivery for tuberculosis therapy. J
Microencapsul. 2014:785–95.
17. Ari A, Arı A. Jet, ultrasonic, and mesh nebulizers: an evaluation of nebulizers
for better clinical outcomes. Eurasian J Pulmonol Eurasian J Pulmonol. 2014;
16:1–7.
18. Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices:
technology update. Med Devices Evid Res. 2015:131–9.
19. Heyder J. Deposition of inhaled particles in the human respiratory tract and
consequences for regional targeting in respiratory drug delivery. Proc Am
Thorac Soc. 2004;1:315–20.
20. MacLoughlin R, Telfer C, Clark A, Fink J. Aerosol: a novel vehicle for
pharmacotherapy in neonates. Curr Pharm Des. 2017;23:5928–34.
21. Daniel RM, Cowan DA. Biomolecular stability and life at high temperatures.
Cell Mol Life Sci. 2000:250–64.
22. de Kruijf W, Ehrhardt C. Inhalation delivery of complex drugs — the next
steps. Curr Opin Pharmacol. 2017:52–7.
23. O’Riordan TG. Formulations and nebulizer performance. Respir Care. 2002;47:
1305–12 discussion 1312-3.
24. Grahmann PR, Braun RK. A new protocol for multiple inhalation of IFN-γ
successfully treats MDR-TB: a case study. Int J Tuberc Lung Dis. 2008;12:636–
44.
25. Diaz KT, Skaria S, Harris K, Solomita M, Lau S, Bauer K, et al. Delivery and
safety of inhaled interferon-γ in idiopathic pulmonary fibrosis. J aerosol med
Pulm drug Deliv. Mary Ann Liebert, Inc. 140 Huguenot street, 3rd floor New
Rochelle, NY 10801 USA ; 2012;25:79–87.
26. O’Mahony AM, Nolan L, O’Driscoll CM, Hibbitts A, Desgranges S, Cryan SA,
et al. Early-stage development of novel Cyclodextrin-siRNA Nanocomplexes
allows for successful Postnebulization transfection of bronchial epithelial
cells. J Aerosol Med Pulm Drug Deliv. 2014;27:466–77.
27. United States pharmacopeia and National Formulary (USP 29-NF 24). 601
aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers.
28. Dugernier J, Hesse M, Vanbever R, Depoortere V, Roeseler J, Michotte JB, et
al. SPECT-CT comparison of lung deposition using a system combining a
vibrating-mesh nebulizer with a Valved holding chamber and a
conventional jet nebulizer: a randomized cross-over study. Pharm Res. 2017;
34:290–300.
29. Branconnier MP, Hess DR. Albuterol delivery during noninvasive ventilation.
Respir Care. 2005;50:1649–53.
30. Bennett G, Joyce M, Sweeney L, MacLoughlin R. In vitro determination of
the Main effects in the Design of High-Flow Nasal Therapy Systems with
respect to aerosol performance. Pulm Ther. 2018;4:73–86.
31. Hart N, Polkey MI, Clément A, Boulé M, Moxham J, Lofaso F, et al. Changes
in pulmonary mechanics with increasing disease severity in children and
Young adults with cystic fibrosis. Am J Respir Crit care med. American
thoracic. Society. 2002;166:61–6.
32. Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in
infectious diseases pathogenesis and potential therapeutic implications.
Cytokine Growth Factor Rev Pergamon. 2011;22:121–30.
33. Hickey AJ, Durham PG, Dharmadhikari A, Nardell EA. Inhaled drug treatment
for tuberculosis: past progress and future prospects. J Control Release. 2016;
240:127–34.
34. MacLoughlin R, Power P, Wolny M, Duffy C. Evaluation of vibrating mesh
nebulizer performance during nasal high flow therapy. J Aerosol Med Pulm
Drug Deliv. 2013;26:A51–2.
35. Martin RJ, Boguniewicz M, Henson JE, Celniker AC, Williams M, Giorno RC, et
al. The effects of inhaled interferon gamma in Normal human airways. Am
Rev Respir Dis. Am Lung Assoc. 1993;148:1677–82.
36. Wan G-H, Fink JB, Lin H-L, Chen Y-H, Liu W-Q, Liu K-Y. Influence of nebulizer
type with different pediatric aerosol masks on drug deposition in a model
of a spontaneously breathing small child. Respir Care. 2012;57:1894–900.
37. Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, et al. The
CXCL10/CXCR3 Axis mediates human lung mast cell migration to asthmatic
Sweeney et al. Respiratory Research           (2019) 20:66 Page 10 of 11
airway smooth muscle. Am J Respir Crit care med. American thoracic.
Society. 2005;171:1103–8.
38. Raju B, Hoshino Y, Kuwabara K, Belitskaya I, Prabhakar S, Canova A, et
al. Aerosolized gamma interferon (IFN-γ) induces expression of the
genes encoding the IFN-γ-inducible 10-Kilodalton protein but not
inducible nitric oxide synthase in the lung during tuberculosis. Infect
Immun. 2004;72:1275–83.
Sweeney et al. Respiratory Research           (2019) 20:66 Page 11 of 11
